23
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Screening for rheumatoid arthritis with finger joint power Doppler ultrasonography: quantification of conventional power Doppler ultrasonographic scoring

, , , , , & show all
Pages 502-506 | Received 09 Mar 2009, Accepted 19 May 2009, Published online: 02 Jan 2014

References

  • Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194): 1932–9.
  • St Clair EW, van der Heijde DM, Smolen JS, Maim RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(10:3432–43.
  • Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, con-trolled trial. Arthritis Rheum. 2005;52(11):3381–90.
  • van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(12):3928–39.
  • Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007 ;66(9) : 1162–7.
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
  • Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8.
  • Grassi W, Filippucci E. Is power Doppler sonography the new frontier in therapy monitoring? Clin Exp Rheumatol. 2003;21(4): 424–8.
  • Stone M, Bergin D, Whelan B, Maher M, Murray J, McCarthy C. Power Doppler ultrasound assessment of rheumatoid hand synovitis. J Rheumatol. 2001;28(9):1979–82.
  • Naredo E, Gamero F, Bonilla G, Uson J, Carmona L, Laffon A. Ultrasonographic assessment of inflammatory activity in rheu-matoid arthritis: comparison of extended versus reduced joint evaluation. Clin Exp Rheumatol. 2005;23(6):881–4.
  • Naredo E, Moller I, Cruz A, Carmona L, Garrido J. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58(8):2248–56.
  • Hameed B, Pilcher J, Heron C, Kiely PD. The relation between composite ultrasound measures and the DA528 score, its com-ponents and acute phase markers in adult RA. Rheumatology (Oxford). 2008;47(4):476–80.
  • Backhaus M, Kamradt T, Sandrock D, Loreck D, Fritz J, Wolf KJ, et al. Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 1999;42(6):1232–45.
  • Wakefield RJ, Brown AK, O'Connor PJ, Emery P. Power Doppler sonography: improving disease activity assessment in inflammatory musculoskeletal disease. Arthritis Rheum. 2003; 48(2):285–8.
  • Ribbens C, Andre B, Marcelis S, Kaye 0, Mathy L, Bonnet V, et al. Rheumatoid hand joint synovitis: gray-scale and power Doppler US quantifications following anti-tumor necrosis factor-alpha treatment: pilot study. Radiology. 2003;229(2):562–9.
  • Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum. 2006;54(1):47–53.
  • Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2958–67.
  • Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D'Agostino MA, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol. 2005; 32(12):2485–7.
  • Wakefield RJ, D'Agostino MA, Iagnocco A, Filippucci E, Backhaus M, Scheel AK, et al. The OMERACT Ultrasound Group: status of current activities and research directions. J Rheumatol. 2007;34(4):848–51.
  • Naredo E, Moller I, Moragues C, de Agustin JJ, Scheel AK, Grassi W, et al. Interobserver reliability in musculoskeletal ultrasonography: results from a "Teach the Teachers" rheuma-tologist course. Ann Rheum Dis. 2006;65(1):14–9.
  • Ostergaard M, Pedersen SJ, Dohn UM. Imaging in rheumatoid arthritis-status and recent advances for magnetic resonance imag-ing, ultrasonography, computed tomography and conventional radiography. Best Pract Res Clin Rheumatol. 2008;22(6):1019–44.
  • Hetland ML, Ejbjerg BJ, Horslev-Petersen K, Jacobsen S, Vest-ergaard A, Junk AG, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheu-matoid arthritis. Results from a 2 year randomized controlled trial (CIMESTRA). Ann Rheum Dis. 2009;68(3):384–90.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.